BG
PTGX icon

Bellevue Group’s Protagonist Therapeutics PTGX Stock Holding History

Bellevue Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.83M Buy
55,682
+41,235
+285% +$4.31M 0.14% 76
2026
Q1 		$1.52M Sell
14,447
-2,096
-13% -$186K 0.04% 86
2025
Q4 		$1.44M Sell
16,543
-4,038
-20% -$331K 0.03% 104
2025
Q3 		$1.37M Buy
20,581
+1,109
+6% +$63K 0.03% 101
2025
Q2 		$1.08M Buy
19,472
+1,850
+10% +$88.8K 0.02% 103
2025
Q1 		$852K Sell
17,622
-6,096
-26% -$255K 0.02% 109
2024
Q4 		$916K Buy
23,718
+11,372
+92% +$496K 0.02% 119
2024
Q3 		$556K Sell
12,346
-2,800
-18% -$113K 0.01% 126
2024
Q2 		$525K Sell
15,146
-4,000
-21% -$117K 0.01% 128
2024
Q1 		$554K Sell
19,146
-10,854
-36% -$295K 0.01% 127
2023
Q4 		$688K Hold
30,000
– – 0.01% 127
2023
Q3 		$500K Buy
+30,000
New +$582K 0.01% 141

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Bellevue Group's PTGX Position: Q2 2026 in Review

Bellevue Group increased its Protagonist Therapeutics (PTGX) stake by 285% in Q2 2026, buying an estimated $4.31M and bringing the position to 55,682 shares worth $6.83M. The position accounts for 0.14% of the portfolio, ranked #76.

Bellevue Group first reported a position in PTGX in Q3 2023 and has held it in 12 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Bellevue Group held 55,682 shares of Protagonist Therapeutics worth $6.83M as of Q2 2026.
  • Bellevue Group bought 41,235 Protagonist Therapeutics shares in Q2 2026, an estimated $4.31M.
  • Protagonist Therapeutics made up 0.14% of Bellevue Group's portfolio in Q2 2026, its #76 holding.
  • Bellevue Group first reported a position in Protagonist Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.